Butidrine
 | |
| Names | |
|---|---|
| IUPAC name
2-(Butan-2-ylamino)-1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanol | |
| Other names
Butedrine; Butydrine; Hydrobutamine; Idrobutamine | |
| Identifiers | |
| 7433-10-5 | |
| 3D model (Jmol) | Interactive image |
| ChEMBL | ChEMBL358930 |
| ChemSpider | 14445 |
| PubChem | 15177 |
| |
| |
| Properties | |
| C16H25NO | |
| Molar mass | 247.38 g·mol−1 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Butidrine (INN) (brand names Betabloc, Butidrate, Recetan), or butedrine or butydrine, also known as hydrobutamine or idrobutamine, is a beta blocker related to pronethalol[1] and propranolol[2] that was developed in the 1960s.[3][4] Similarly to certain other beta blockers, butidrine also possesses local anesthetic properties.[5]
References
- ↑ James A. Bristol (1986). Cardiovascular drugs. John Wiley & Sons, Incorporated. p. 111. ISBN 978-0-471-09228-5.
- ↑ Drug Metabolism Reviews. Marcel Dekker. 1972.
- ↑ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 58–. ISBN 978-94-011-4439-1.
- ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 197–. ISBN 978-1-4757-2085-3.
- ↑ Robert Charlier (1971). Antianginal drugs: pathophysiological, haemodynamic, methodological, pharmacological, biochemical and clinical basis for their use in human therapeutics. Springer-Verlag. ISBN 978-3-540-05365-1.
This article is issued from Wikipedia - version of the 9/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.